Validation Digital Bio-markers During Sulforaphane Treatment.

Autism Spectrum Disorder Clinical Trial

Official title:

A Pilot Project to Validate Digital Bio-markers as a Tool to Measure Improvement in Core Symptoms of Autism During Sulforaphane Treatment.

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04805957
• Other study ID #: Pro2019001854
• Status: Enrolling by invitation
• Phase: N/A
• Start date: July 7, 2022
• Est. completion date: June 1, 2025

Study information

• Verified date: June 2024
• Source: Rutgers, The State University of New Jersey
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the research is to determine if changes seen during sulforaphane treatment (a compound that comes from eating certain vegetables) can better be understood using digital biomarkers. These digital biomarkers are things like heart rate, muscle movement etc. and are measured using non-invasive devices (like a watch) and are aimed at complementing the traditional clinical scores already in use in current trials (e.g. Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and Ohio Autism Clinical Impressions Scale (OACIS)).

Description:

This study is a pilot open label treatment trial with SF (sulforaphane) in 10 individuals that have completed with moderate to severe autism, age 13-30 years that have completed participation in ClinicalTrials.gov Identifier: NCT02677051. This study will measure digital biomarkers of the nervous systems. Digital biomarkers are obtained by using non-invasive wireless (wearable, like wearing a watch) biosensors that co-register in tandem multiple biorhythms self-generated by the person's nervous systems. These sensors gather a very large amount of data from measures such as EEG (electroencephalogram), EKG (electrocardiogram), kinematics and others. These measures are done at the same time as the clinical evaluations and so results can be compared. Because the data are based on the unique fingerprint-like signatures of the person's nervous systems, it is possible to ascertain the person's progression in response to treatment and compare it to baseline states. The project will also compare these self-emerging clusters between subjects, possibly identifying patterns that correlate with sub-phenotypes or with similarities in response to treatment. Changes in things such as natural behaviors, an individual's ability or desire to interact socially and ability or desire to communicate will alter the signature profiles from baseline. Since these changes are dynamic in nature, trends of the evolving patterns and separate changes that are a consequence of the treatment vs. changes that are part of the natural neurodevelopment can be detected. This may be a valuable tool in future studies of underlying etiology. The technology used to perform these measures and the software to analyze the data are evolving rapidly. Last, with the characterized signatures and possibly overlapping patterns generated in this and in other projects it is foreseeable that a clinically relevant tool for measures in autism will follow.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 10
• Est. completion date: June 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 13 Years to 30 Years

Eligibility

Inclusion Criteria:

• Autistic disorder diagnosis.

• Age between 13-30 years.

• Male gender.

• Participated in clinical trial NCT02677051

Exclusion Criteria:

• Those that started or continued taking Avmacol® or similar broccoli extracts since leaving our double-blind study.

• Absence of a parent or legal guardian and consent,

• Those that can not or will not complete all visits and adherence to study regimen.

• Seizure within 2 years of screening,

• History of chronic kidney, liver or thyroid disease.

• Impaired renal function (serum creatinine> 1.2 mg/dl).

• Impaired hepatic function (> 2x upper limit of normal).

• Impaired thyroid function (TSH outside normal limits).

• Current infection or treatment with antibiotics.

• Chronic medical disorder (e.g., cardiovascular disease, stroke or diabetes) or major surgery within 3 months prior to enrollment.

• Less than 13 years or more than 30 years of age.

• Female gender.

• A diagnosis of autism spectrum disorder other than autistic disorder, for example, Asperger, PDD-NOS ( Pervasive Developmental Disorder-Not Otherwise Specified) etc.

Related Conditions & MeSH terms

• Autism
• Autism Spectrum Disorder
• Autistic Disorder

Intervention

Dietary Supplement:
• Sulforaphane
Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.

Locations

Country	Name	City	State
United States	Rutgers-RWJMS Department of Neurology	Piscataway	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Rutgers, The State University of New Jersey

Country where clinical trial is conducted

United States, 

References & Publications (3)

Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, Zimmerman AW. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15550-5. doi: 10.1073/pnas.1416940111. Epub 2014 Oct 13. — View Citation

Torres EB, Brincker M, Isenhower RW, Yanovich P, Stigler KA, Nurnberger JI, Metaxas DN, Jose JV. Autism: the micro-movement perspective. Front Integr Neurosci. 2013 Jul 24;7:32. doi: 10.3389/fnint.2013.00032. eCollection 2013. — View Citation

Torres EB. Atypical signatures of motor variability found in an individual with ASD. Neurocase. 2013 Apr;19(2):150-65. doi: 10.1080/13554794.2011.654224. Epub 2012 May 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aberrant Behavior Checklist (ABC)	Rating scale to measure severity aberrant behaviors	Baseline.
Primary	Aberrant Behavior Checklist (ABC)	Rating scale to measure severity aberrant behaviors	Week 6.
Primary	Aberrant Behavior Checklist (ABC)	Rating scale to measure severity aberrant behaviors	Week 12, end of treatment.
Primary	Aberrant Behavior Checklist (ABC)	Rating scale to measure severity aberrant behaviors	Week 16.
Primary	Social Responsiveness Scale (SRS)	Rating scale to measure social interaction.	Baseline.
Primary	Social Responsiveness Scale (SRS)	Rating scale to measure social interaction.	Week 6.
Primary	Social Responsiveness Scale (SRS)	Rating scale to measure social interaction.	Week 12, end of treatment.
Primary	Social Responsiveness Scale (SRS)	Rating scale to measure social interaction.	Week 16.
Primary	Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)	Rating scale to measure autism severity and changes in severity.	Baseline.
Primary	Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)	Rating scale to measure autism severity and changes in severity.	Week 6.
Primary	Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)	Rating scale to measure autism severity and changes in severity.	Week 12, end of treatment.
Primary	Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)	Rating scale to measure autism severity and changes in severity.	Week 16.
Primary	Digital Biomarkers	Non-invasive biosensor measurements of micro-movements.	Baseline.
Primary	Digital Biomarkers	Non-invasive biosensor measurements of micro-movements.	Week 6.
Primary	Digital Biomarkers	Non-invasive biosensor measurements of micro-movements.	Week 12, end of treatment.
Primary	Digital Biomarkers	Non-invasive biosensor measurements of micro-movements.	Week 16.
Primary	EEG	Electroencephalogram (EEG) measures electrical activity of the brain.	Baseline
Primary	EEG	Electroencephalogram (EEG) measures electrical activity of the brain.	Week 6.
Primary	EEG	Electroencephalogram (EEG) measures electrical activity of the brain.	Week 12, end of treatment.
Primary	EEG	Electroencephalogram (EEG) measures electrical activity of the brain.	Week 16.
Primary	EKG	Electrocardiogram (ECG or EKG) measures electrical signals from the heart.	Baseline
Primary	EKG	Electrocardiogram (ECG or EKG) measures electrical signals from the heart.	Week 6.
Primary	EKG	Electrocardiogram (ECG or EKG) measures electrical signals from the heart.	Week 12, end of treatment.
Primary	EKG	Electrocardiogram (ECG or EKG) measures electrical signals from the heart.	Week 16.
Primary	Electrophysiological recordings.	Measurement of electrical activity in Tissue.	Baseline
Primary	Electrophysiological recordings.	Measurement of electrical activity in Tissue.	Week 6.
Primary	Electrophysiological recordings.	Measurement of electrical activity in Tissue.	Week 12, end of treatment.
Primary	Electrophysiological recordings.	Measurement of electrical activity in Tissue.	Week 16.